ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.
ProImmune has developed the service in response to increasing demand for modified versions of the Company's growing range of immunology platform assays, to suit particular needs. In many cases ProImmune's standard assays can be readily adapted to meet the customer's requirements, and therefore deployed rapidly, enabling fast implementation of unique protocols that could otherwise take months or years to develop and qualify in house.
ProImmune's existing immunology assay services include immune modulation assays, managing drug immunogenicity risk, characterising the immune response to new antigens, and a wide range of immune monitoring assays.
Dr Nikolai Schwabe, CEO of ProImmune, commented: "The introduction of the Special Assay Service highlights the evolution of assay customization into a formal discipline within the company, and demonstrates our commitment to delivering the most innovative and comprehensive service available for characterising immune responses. As with our standard assays, our technically-trained customer service staff is able to understand the core objectives and issues in a project from the outset and are committed to rapidly providing detailed proposals to our customers' RFPs."